ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
- PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors.Journal for immunotherapy of cancer · 2025Article
- Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy.Advanced functional materials · 2024Article
- A structural perspective of how T cell receptors recognize the CD1 family of lipid antigen-presenting molecules.The Journal of biological chemistry · 2024Review
- The role of NKT cells in gastrointestinal cancers.Oncoimmunology · 2022Review
- Article
- Synthetic preparation and immunological evaluation of β-mannosylceramide and related N-acyl analogues.Organic & biomolecular chemistry · 2020Article
- Complementary approaches to study NKT cells in cancer.Methods in enzymology · 2020Article
- Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.Frontiers in immunology · 2019Article
- Tissue-Specific Roles of NKT Cells in Tumor Immunity.Frontiers in immunology · 2018Review
- Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Immunogenetics · 2016Review
- Antigen specificity of invariant natural killer T-cells.Biomedical journal · 2015Review
- The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.Cancer immunology, immunotherapy : CII · 2014Review
- NKT cell networks in the regulation of tumor immunity.Frontiers in immunology · 2014Review
- Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.Expert review of vaccines · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeMost studies characterizing antitumor properties of invariant natural killer T (iNKT) cells have used the agonist, α-galactosylceramide (α-GalCer). However, α-GalCer induces strong, long-lasting anergy of iNKT cells, which could be a major detriment for clinical therapy. A novel iNKT cell agonist, β-mannosylceramide (β-ManCer), induces strong antitumor immunity through a mechanism distinct from that of α-GalCer. The objective of this study was to determine whether β-ManCer induces anergy of iNKT cells. EXPERIMENTAL
designInduction of anergy was determined by ex vivo analysis of splenocytes from mice pretreated with iNKT cell agonists as well as in the CT26 lung metastasis in vivo tumor model.
resultsβ-ManCer activated iNKT cells without inducing long-term anergy. The transience of anergy induction correlated with a shortened duration of PD-1 upregulation on iNKT cells activated with β-ManCer, compared with α-GalCer. Moreover, whereas mice pretreated with α-GalCer were unable to respond to a second glycolipid stimulation to induce tumor protection for up to 2 months, mice pretreated with β-ManCer were protected from tumors by a second stimulation equivalently to vehicle-treated mice.
conclusionsThe lack of long-term functional anergy induced by β-ManCer, which allows for a second dose to still give therapeutic benefit, suggests the strong potential for this iNKT cell agonist to succeed in settings where α-GalCer has failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.